As of the 28 January 2025 revision it is indicated not only for glycaemic control in type 2 diabetes, but also to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
They're only used if you choose to turn them on and may be set by us or by approved third-party partners.Cookie Details Functional cookies These cookies remember your choices, like your language or region, to make the website easier to use and more personalised for you
The trial involved more than 3500 participants with type 2 diabetes and chronic kidney disease (CKD) from 28 countries, including Australia, ultimately finding the dose of semaglutide reduced the risk of major kidney events by 24%
This physician oversight continues throughout the journey, with dosage adjustments, guidance, and progress tracking
Semaglutide works by mimicking a hunger hormone in the body that senses when there is food in the intestine, allowing the pancreas to make insulin